申请人:Cancer Research Campaign Technology Limited
公开号:US05260291A1
公开(公告)日:1993-11-09
[ 3H]-Imidazo[ 5,1-d] -1,2,3,5-tetrazin-4-one derivatives of the formula: ##STR1## wherein R.sup.1 represents hydrogen, or an alkyl, alkenyl or alkynyl group containing up to 6 carbon atoms, each such group being unsubstituted or substituted by from one to three substituents selected from halogen atoms, alkoxy, alkylthio, alkylsulphinyl and alkylsulphonyl groups containing up to 4 carbon atoms, and optionally substituted phenyl groups, or R.sup.1 represents a cycloalkyl group containing from 3 to 8 carbon atoms, and R.sup.2 represents a carbamoyl group optionally N-substituted by one or two groups selected ftom alkyl and alkenyl groups containing up to 4 carbon atoms, and cycloalkyl groups containing 3 to 8 carbon atoms, are new therapeutically useful compounds possessing antineoplastic and immunomodulatory activity.
该公式的[3H]-Imidazo[5,1-d]-1,2,3,5-四唑-4-酮衍生物:其中R1代表氢,或者是含有最多6个碳原子的烷基,烯基或炔基,每个这样的基团未被取代或被从卤素原子,烷氧基,烷硫基,烷基亚磺酰基和烷基磺酰基中选择的1到3个取代基取代,这些取代基含有最多4个碳原子,并且可以是取代的苯基,或R1代表含有3到8个碳原子的环烷基,R2代表一个氨基甲酰基团,该氨基甲酰基团可以被一个或两个选择自含有最多4个碳原子的烷基和烯基团和含有3到8个碳原子的环烷基的基团取代,是新的具有抗肿瘤和免疫调节活性的治疗上有用的化合物。